Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (597)	12/19/1997 2:54:00 PM
From: John McCarthy	Read Replies (2) \| Respond to of 887

Baird, I'm staying in for two reasons. At this point, NO ONE knows HOW WELL the product works versus a control group. As explained succinctly in a previous post, the company did one kind of math, and the board another. The FDA will hold the line, but if I believe what I have read previously, if the FDA said go ahead and submit with the small group, there was some disconnect between the Advisory board and the FDA folks who had guided DEPO along. Or else, DEPO's management is worse than I think. Your previous posts have covered the issue of side effects. Regards, John